INNOSCIENCE

英诺赛科今日开盘后迅速走弱，最新报 40.36 港元，较前收 36.94 港元上涨 9.26%，但盘中一度下探至 39.68 港元，距 52 周低位 36.68 港元仅差 8.17%，而距 52 周高位 106.10 港元已跌去 61.96%。早盘首笔成交于 39.98 港元，随后反弹至 40.36 港元，显示多空在 40 港元附近激烈博弈。消息面上，近期公司遭遇多重专利诉讼冲击：美国国际贸易委员会已裁定禁止其侵权 GaN 产品在美销售，德国慕尼黑法院也颁布禁令，但公司同时推动法院禁令产品从中国电子展上移除，部分抵消了负面情绪。财报方面，Q4 2025 营收同比增长 55.84% 至约 3.67 亿港元，净亏损同比收窄 22.81%，每股亏损-0.2567 港元，经营现金流尚未转正，但亏损幅度持续收窄。当前股价低于 MA20（47.209 港元）和 MA60（61.40 港元），YTD 累计下跌 46.08%，估值上 PB 为 7.86 倍，仍处于亏损状态。不过，国泰海通与高盛近期均给予买入评级，显示机构对长期技术前景的认可。

Innoscience Technology experienced a surge-and-fall session in Hong Kong today. The stock spiked to an intraday high of HKD 39.92 in early morning trading before steadily declining, reaching a new 52-week low of HKD 36.68 in the afternoon session, closing at HKD 36.86, down 6.6%, representing a 65.3% retreat from its 52-week high of HKD 106.1. The ongoing patent litigation overhang continues to weigh on sentiment, following last week's U.S. International Trade Commission ruling banning its infringing GaN products from the U.S. market, coupled with a German court decision prohibiting sales of related products in Germany. Despite Q4 2025 operating revenue surging 55.8% YoY to HKD 367 million and net loss narrowing 22.8% YoY to HKD 229 million, the stock has broken below both the 20-day (HKD 48.24) and 60-day (HKD 61.87) moving averages, with a YTD decline of 50.8%. However, the company's success in enforcing court-ordered removal of Infineon's infringing GaN products at a Chinese exhibition earlier this month had sparked an 8% gain, suggesting the patent battle remains a two-way dynamic.

InnoScience (Suzhou) Technology opened lower and extended losses in the Hong Kong morning session, trading at HK$41.90 as of 10:35 BJ, down approximately 5.0%, driven by a series of unfavorable international patent rulings. Following the US ITC's confirmation of a ban on its GaN products in the US, a Munich court also barred the company from selling its GaN products in Germany, adding to sector-wide pullback pressure. The stock is now trading just above its 52-week low of HK$41.10, with a decline of 60.51% from its 52-week high of HK$106.10 and a year-to-date drop of 44.02%. Financially, revenue growth continued at 55.84% YoY in Q4 to approximately HK$367 million, though net loss remained at ~HK$229 million, with a net profit margin of -62.41%. While the patent headwinds are severe, the company previously secured a favorable court ruling in Germany that forced the removal of Infineon's infringing products, suggesting ongoing legal countermeasures.

InnoScience opened lower and fell steadily during the morning session, closing at HK$41.78, down 5.0% from the previous close of HK$44.00, driven by the US ITC's final determination banning its patent-infringing GaN products from the US market, coupled with a Munich court ruling prohibiting sales in Germany, which together intensified investor concerns over patent litigation. The company's Q4 revenue grew 55.8% YoY to HK$367 million, but net loss remained at HK$229 million, with EPS of -HK$0.2567, narrowing 22.8% YoY, while fundamentals showed no significant improvement. The stock has fallen 60.6% from its 52-week high of HK$106.1, sits just above the 52-week low of HK$41, and trades well below the 20-day MA of HK$51.58, indicating a weak technical position. However, a German court in July cleared InnoScience of infringing Infineon patents, and Infineon's infringing products were subsequently removed from an exhibition, suggesting some patent disputes may see reversals.

InnoScience (Suzhou) Technology opened lower and continued its decline during the Hong Kong morning session, dropping approximately 5% to HK$43.48 by 10:42 BJ time, with intraday low at HK$43.48, turnover of 1.4969 million shares and HK$66.1 million. The stock has fallen 59% from its 52-week high of HK$106.1 on September 2, 2025, and trades well below its 20-day (HK$52.6) and 60-day (HK$63.52) moving averages, reflecting weak technical momentum. Headwinds from patent litigation remain key: the US ITC confirmed a ban on certain GaN products, and a Munich court barred sales in Germany, though the company secured removal of Infineon's infringing products from a Chinese exhibition. Financially, Q4 2025 revenue grew 55.84% YoY to HK$366.9 million, while net loss narrowed 22.81% YoY to HK$229 million, with EPS loss of HK$0.2567, signaling improving but still negative profitability. The stock trades at a PB of 8.54x and negative PE. However, Guotai Haitong and Goldman Sachs maintain Buy ratings, and the trustee added HK$39 million in H-shares under the 2025 award plan, suggesting insider confidence.